ACHILLES THERAPEUTICS ($ACHL) is expected to release its quarterly earnings data on Wednesday, April 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.37 per share.
You can see Quiver Quantitative's $ACHL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACHILLES THERAPEUTICS Hedge Fund Activity
We have seen 6 institutional investors add shares of ACHILLES THERAPEUTICS stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP removed 1,108,767 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,130,942
- ARTAL GROUP S.A. removed 755,375 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $770,482
- RENAISSANCE TECHNOLOGIES LLC removed 90,900 shares (-14.2%) from their portfolio in Q4 2024, for an estimated $103,625
- UBS GROUP AG removed 65,700 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $67,014
- ACADIAN ASSET MANAGEMENT LLC removed 58,996 shares (-23.5%) from their portfolio in Q4 2024, for an estimated $67,255
- BNP PARIBAS FINANCIAL MARKETS added 50,189 shares (+inf%) to their portfolio in Q4 2024, for an estimated $57,215
- TWO SIGMA INVESTMENTS, LP added 40,388 shares (+190.1%) to their portfolio in Q4 2024, for an estimated $46,042
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
